Patricia de Crémoux

ORCID: 0000-0003-0061-8700
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Genomics and Diagnostics
  • Estrogen and related hormone effects
  • Cancer-related Molecular Pathways
  • Cancer Cells and Metastasis
  • Cancer Treatment and Pharmacology
  • Cervical Cancer and HPV Research
  • Advanced Breast Cancer Therapies
  • Epigenetics and DNA Methylation
  • Lung Cancer Treatments and Mutations
  • Molecular Biology Techniques and Applications
  • Autophagy in Disease and Therapy
  • Breast Lesions and Carcinomas
  • Colorectal Cancer Treatments and Studies
  • Monoclonal and Polyclonal Antibodies Research
  • Medical Imaging Techniques and Applications
  • Lung Cancer Research Studies
  • Radiomics and Machine Learning in Medical Imaging
  • Gene expression and cancer classification
  • Health Systems, Economic Evaluations, Quality of Life
  • Lymphoma Diagnosis and Treatment
  • Genetic factors in colorectal cancer
  • Glioma Diagnosis and Treatment
  • Cancer Diagnosis and Treatment

Université Paris Cité
2011-2023

Hôpital Saint-Louis
2012-2023

Institut Curie
2006-2019

Assistance Publique – Hôpitaux de Paris
2011-2019

Centre Jean Perrin
2019

Institut Bergonié
2019

Délégation Paris 7
2012-2018

Sorbonne Paris Cité
2012-2018

Centre National de la Recherche Scientifique
2004-2018

Inserm
1994-2018

Abstract Purpose: To establish a panel of human breast cancer (HBC) xenografts in immunodeficient mice suitable for pharmacologic preclinical assays. Experimental Design: 200 samples HBCs were grafted into Swiss nude mice. Twenty-five transplantable established (12.5%). Their characterization included histology, p53 status, genetic analysis by array comparative genomic hybridization, gene expression Western blotting, and quantitative reverse transcription-PCR. Biological profiles nine...

10.1158/1078-0432.ccr-07-0078 article EN Clinical Cancer Research 2007-07-01

Abstract Purpose: Circulating tumor cells in blood from metastatic breast cancer patients have been reported as a surrogate marker for response and shorter survival. The aim of this study was to determine whether circulating are present the with large operable or locally advanced before neoadjuvant chemotherapy after surgery. Experimental Design: Blood samples 7.5 mL were obtained on CellSave tubes included phase II trial (REMAGUS 02). immunomagnetically separated fluorescently stained by...

10.1158/1078-0432.ccr-08-0030 article EN Clinical Cancer Research 2008-11-01

Epithelial-to-mesenchymal transition (EMT) mediates cancer cell invasion, metastasis, and drug resistance, but its impact on immune surveillance has not been explored. In this study, we investigated the functional consequences of mode epithelial plasticity targeted lysis by cytotoxic T lymphocytes (CTL). Acquisition EMT phenotype in various derivatives MCF-7 human breast cells was associated with dramatic morphologic changes actin cytoskeleton remodeling, CD24(-)/CD44(+)/ALDH(+) stem...

10.1158/0008-5472.can-12-2432 article EN Cancer Research 2013-02-23

Abstract Purpose: The presence of tumor cells in bone marrow has been reported to represent an important prognostic indicator breast cancer, but the clinical significance circulating peripheral blood is less well known. aim this study was evaluate feasibility identifying cytokeratin (CK)-expressing with automat-assisted immunohistochemical detection system and compare it samples. Experimental Design: Cytospun Ficoll fractions were obtained simultaneously 114 cancer patients at different...

10.1158/1078-0432.ccr-0102-03 article EN Clinical Cancer Research 2004-02-15

Abstract Introduction Typical medullary breast carcinoma (MBC) has recently been recognized to be part of the basal-like spectrum, a feature in agreement with high rate TP53 mutations previously reported MBCs. The present study was therefore designed identify phenotypic and genetic alterations that distinguish MBCs from carcinomas (BLC). Methods Expression levels estrogen receptor (ER), progesterone (PR), ERBB2, TP53, cytokeratins (KRTs) 5/6, 14, 8/18, epidermal growth factor KIT, as well...

10.1186/bcr1666 article EN cc-by Breast Cancer Research 2007-04-06

Abstract Introduction Identification of new therapeutic agents for breast cancer (BC) requires preclinical models that reproduce the molecular characteristics their respective clinical tumors. In this work, we analyzed genomic and gene expression profiles human BC xenografts corresponding patient Methods Eighteen were obtained by grafting tumor fragments from patients into Swiss nude mice. Molecular characterization tumors was performed DNA copy number analysis using Affymetrix Microarrays....

10.1186/bcr3095 article EN cc-by Breast Cancer Research 2012-01-16

To compare the sensitivity, specificity, and interobserver reliability of conventional cervical smear tests, monolayer cytology, human papillomavirus testing for screening cancer.Cross sectional study in which three techniques were performed simultaneously with a reference standard (colposcopy histology).Public university private practices France, complete independence from suppliers.828 women referred colposcopy because previously detected cytological abnormalities 1757 attending routine...

10.1136/bmj.326.7392.733 article EN BMJ 2003-04-03

To document whether c-erbB-2 over-expression or p53 accumulation in tumour cells was predictive of response to chemo- radiotherapy, we analyzed a population patients with breast cancer assigned neo-adjuvant therapy (median follow-up: 54 months). T2/T3-N0N1b-M0 tumours (329 cases) were treated either by FAC chemotherapy radiotherapy before surgery, and the clinical classified as complete incomplete. Expression retrospectively evaluated immunohistochemistry. Proliferation rate assessed means...

10.1002/(sici)1097-0215(19980220)79:1<27::aid-ijc6>3.0.co;2-y article EN International Journal of Cancer 1998-02-20

We present a fully automated system performing continuous sampling, reagent mixing, and polymerase chain reaction (PCR) in microdroplets transported immiscible oil. Sample preparation analysis are totally automated, using an original injection method from modified 96-well plate layered with three superimposed liquid layers in-capillary laser-induced fluorescence endpoint detection. The process is continuous, allowing sample droplets to be carried uninterruptedly into the zone while new drops...

10.1021/ac061205e article EN Analytical Chemistry 2006-10-19

To investigate whether integration of HPV DNA in cervical carcinoma is responsible for structural alterations the host genome at insertion site, a series 34 primary carcinomas and eight cancer-derived cell lines were analysed. copy number profiles assessed using Affymetrix GeneChip Human Mapping 250K Sty array. 16, 18 or 45 sites determined DIPS-PCR technique. The status was classified as follows: no change, amplification, transition normal/gain, normal/loss gain/LOH. A single site found...

10.1002/path.2713 article EN The Journal of Pathology 2010-03-20

Molecular apocrine (MA) tumors are estrogen receptor (ER) negative breast cancers characterized by androgen (AR) expression. We analyzed a group of 58 transcriptionally defined MA and proposed new tool to identify these tumors.We performed quantitative reverse transcription PCR (qRT-PCR) for ESR1, AR, FOXA1 AR-related genes, immunohistochemistry (IHC) ER, PR, Human Epidermal Growth Factor Receptor 2 (HER2), CK5/6, CK17, EGFR, Ki67, GCDFP15 we clinical features.MA were all ESR1(-) AR(+)...

10.1186/bcr3421 article EN cc-by Breast Cancer Research 2013-05-11

Purpose To investigate parameters based on fluorine 18 fluorodeoxyglucose (FDG) positron emission tomographic (PET) imaging that are best correlated with pathologic complete response (PCR) in human epidermal growth factor receptor type 2 (HER2)–positive cancer and triple-negative breast (TNBC) partial or ER-positive/HER2-negative cancer. Materials Methods This study was approved by institutional review board waivers of informed written consent included consecutive patients treated...

10.1148/radiol.2015141638 article EN Radiology 2015-04-27
Coming Soon ...